E Bu Shi Cao

E Bu Shi Cao (Centipeda minima) is the dried whole herb of Centipeda minima (L.) A. Braun & Asch., an annual creeping herbaceous plant in the family Asteraceae. In the traditional TCM classification system, E Bu Shi Cao is considered pungent in flavor with a warm nature. It enters the Lung and Liver meridians, giving it a central role in formulas that address exterior Wind disorders, nasal congestion, cough, and phlegm accumulation.

Botanical description: Centipeda minima is a small, annual, creeping herb that forms dense mats along the ground. The stems are slender, branched, and rooting at the nodes, typically 5–20 cm long. The leaves are alternate, small (0.5–1.5 cm long), spatulate to obovate, with coarsely toothed margins and a slightly fleshy texture. The flower heads are tiny, globose, yellowish-green, and sessile, borne in the leaf axils. The plant produces small, dry achenes as fruits. The entire aerial portion is collected for medicinal use. When dried, the herb appears as a greenish-brown mass of slender stems, small crinkled leaves, and minute flower heads, with a characteristic aromatic odor and a slightly pungent, warm taste.

Habitat and cultivation: C. minima is widely distributed across Asia, including China, Japan, Korea, India, and Southeast Asia, as well as Australia and parts of the Pacific islands. In China, it is found throughout most provinces, growing in moist, open environments such as field margins, roadsides, stream banks, and waste areas. The plant prefers warm, humid conditions and is typically collected in summer and autumn when it is in full bloom. The whole plant is harvested, cleaned, and dried in the shade or under the sun for medicinal use.

Quality markers: The Chinese Pharmacopoeia specifies that high-quality E Bu Shi Cao should have a greenish-brown color, a characteristic aromatic odor, and a slightly pungent, warm taste. The material should be free from excessive soil, mold, and insect damage. Quality control standards include limits on moisture content and chemical markers for authentication purposes. The pharmacopoeia also specifies minimum content requirements for the volatile oil fraction.

In the traditional Chinese medicine theoretical framework, E Bu Shi Cao is understood in terms of its effects on specific patterns of disharmony (zheng). Because E Bu Shi Cao enters the Lung and Liver meridians and has a pungent, warm quality, it is traditionally indicated for a range of patterns involving exterior Wind invasion, nasal congestion, and phlegm accumulation.

Releasing the exterior and dispersing Wind: E Bu Shi Cao is considered one of the important herbs in TCM for releasing the exterior and dispersing Wind. In TCM theory, when exterior Wind-Cold or Wind-Heat invades the body, symptoms such as nasal congestion, runny nose, sneezing, headache, and chills may appear. E Bu Shi Cao is traditionally used to dispel Wind, open the nasal passages, and relieve these symptoms. It is particularly valued for its ability to reach the nasal and sinus region, making it a key herb for nasal disorders.

Relieving nasal congestion and treating rhinitis: E Bu Shi Cao is most famous in TCM for its traditional use in treating allergic rhinitis, sinusitis, and nasal congestion. It is believed to open the nasal passages, reduce nasal secretions, and alleviate sneezing. In clinical practice, the powdered herb is often used for nasal insufflation (snuffing), a method of direct application to the nasal mucosa. It may also be used in decoction form for oral administration. It is frequently combined with Xin Yi (Magnolia flower) and Jing Jie (Schizonepeta) in formulas targeting nasal congestion and allergic rhinitis.

Stopping cough and resolving phlegm: When Wind-Cold or Wind-Heat invades the Lung, symptoms such as cough, chest congestion, and phlegm accumulation may appear. E Bu Shi Cao is traditionally used to stop cough, resolve phlegm, and promote the smooth flow of Lung Qi. It is particularly indicated for coughs associated with nasal congestion and sinus drainage, where the cough is aggravated by post-nasal drip. In classical formulas, it is often combined with herbs that transform phlegm and direct Lung Qi downward.

Clearing the head and eyes: E Bu Shi Cao enters the Liver meridian and is traditionally used for conditions affecting the head and eyes. In TCM theory, when Wind-Heat or Liver-related patterns affect the upper body, symptoms such as headache, eye redness, and visual discomfort may appear. E Bu Shi Cao is traditionally used to disperse Wind-Heat from the head region, relieve headache, and soothe eye discomfort. It is sometimes used in combination with Chan Tui (Cicada Slough) for Wind-related eye conditions.

Classical literature references: The Ben Cao Gang Mu (Compendium of Materia Medica, 1596 CE) by Li Shizhen recorded E Bu Shi Cao's traditional use for "relieving nasal congestion, dispersing Wind, and resolving phlegm." The Ben Cao Shi Yi (Supplement to the Materia Medica) noted its effectiveness in treating nasal obstruction and headache. The Sheng Nong Ben Cao Jing (Divine Farmer's Materia Medica Classic) classified it as a middle-grade herb and recorded its traditional use for "dispersing Wind-Cold, opening the nasal passages, and alleviating cough."

E Bu Shi Cao contains a range of bioactive compounds that have been the subject of pharmacological investigation. The following overview summarizes the major chemical constituents identified in the whole herb of Centipeda minima and what is currently known about them from published research.

Brevilin A (6-O-angeloylplenolin): Brevilin A is a sesquiterpene lactone and one of the principal pharmacologically active constituents identified in E Bu Shi Cao. It has been studied in pre-clinical research for a range of potential pharmacological activities, including anti-inflammatory, anti-cancer, and immunomodulatory effects. Brevilin A has been shown to inhibit STAT3 and JAK signaling pathways, suppress inflammatory cytokine production, and induce apoptosis in various cancer cell lines. A 2024 case series reported successful use of brevilin A in pediatric alopecia areata. However, most evidence comes from animal and in-vitro studies; robust human clinical data are limited.

Arnicolide C and arnicolide D: These sesquiterpene lactones, closely related to brevilin A, have attracted research interest for their potential anti-cancer properties. Arnicolide C has been studied for its ability to induce ROS-mediated modulation of PI3K/Akt and MAPK pathways in hepatocellular carcinoma models. Arnicolide D has demonstrated multi-targeted anti-cancer activity against osteosarcoma and other cancer types through PI3K/Akt/mTOR pathway inhibition. Their clinical relevance in the context of whole-herb E Bu Shi Cao preparations is not well established.

6-O-angeloylplenolin: 6-O-angeloylplenolin (6-OAP) is another sesquiterpene lactone from E Bu Shi Cao that has been studied for its potential to enhance the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. Pre-clinical research has suggested that 6-OAP may improve the anti-tumor activity of CD8+ T cells when combined with anti-PD-L1 antibodies. The clinical significance of these findings for human immune-oncology applications has not been established.

Flavonoids and other constituents: E Bu Shi Cao also contains flavonoids, triterpenoids, sterols, and volatile oils. The volatile oil fraction is believed to contribute to the herb's characteristic aromatic odor and its traditional use in opening the nasal passages. Most research on these secondary compounds remains at the pre-clinical stage, and their specific contributions to the pharmacological profile of whole-herb E Bu Shi Cao are not fully understood.

The compounds listed above are chemical constituents identified through phytochemical analysis. Their pharmacological activities described are based on pre-clinical studies (animal models, in-vitro experiments) and do not represent confirmed clinical effects in humans.

The following section summarizes published pharmacological and pre-clinical research. Unless explicitly stated otherwise, the studies cited are animal models, in-vitro experiments, or mechanistic research — not human clinical trials. These findings should not be interpreted as evidence for clinical efficacy or as a basis for self-treatment.

Anti-allergic and anti-inflammatory effects in allergic rhinitis: A 2025 study by Zhang et al. published in the International Journal of Molecular Sciences(PMID: 40943597) compared the effects of fresh and dried Centipeda minima extracts in an allergic rhinitis model. The study identified neocnidilide and 6-gingerol as key bioactive compounds, and demonstrated that both fresh and dried extracts modulated Th1/Th2 immune balance via NF-κB and JAK-STAT pathways. The dried extract showed stronger anti-allergic effects. While these findings are scientifically interesting, their clinical significance for human allergic rhinitis has not been established through large-scale clinical trials.

Anti-cancer activity of brevilin A and sesquiterpene lactones: Multiple pre-clinical studies have investigated the anti-cancer potential of E Bu Shi Cao constituents. A 2025 study by Wang et al. in the Journal of Ethnopharmacology(PMID: 39722328) demonstrated that Centipeda minima extracts and sesquiterpene lactones suppressed the Skp2/p27 signaling pathway in non-small cell lung cancer. Another 2025 study by Wei et al. in Phytomedicine (PMID: 39954620) showed thatC. minima extract exhibited anti-liver cancer effects via the ER stress/HMOX1/Fe(2+)/ROS pathway. A 2024 study by Wang et al. in Phytomedicine (PMID: 38968790) reported that C. minima and 6-O-angeloylplenolin enhanced the efficacy of immune checkpoint inhibitors in non-small cell lung cancer models. Despite these promising pre-clinical signals, no large-scale human clinical trials have confirmed these effects.

Brevilin A as a JAK inhibitor: Brevilin A has been identified as a natural JAK inhibitor. A 2024 case series by Matteini et al. in Clinical, Cosmetic and Investigational Dermatology (PMID: 39387062) reported successful treatment of pediatric alopecia areata with brevilin A. This is one of the few human studies available, though it is a small case series and not a controlled clinical trial. Additional pre-clinical research has demonstrated brevilin A's ability to inhibit STAT3 and STAT1 signaling, as well as JAKs tyrosine kinase activity.

Network pharmacology and mechanistic studies: A 2026 study by Huang et al. in Current Computer-Aided Drug Design (PMID: 39411942) used network pharmacology approaches to investigate the mechanisms of Centipeda minimain treating nasopharyngeal carcinoma, identifying key active ingredients, potential targets, and signaling pathways. Such computational studies provide hypotheses for future experimental validation but do not constitute clinical evidence.

What the research does NOT show: Despite promising pre-clinical signals, the research on E Bu Shi Cao and its active compounds does NOT demonstrate conclusive clinical efficacy for any specific disease in humans. There is no robust evidence from large-scale, randomized, placebo-controlled clinical trials that E Bu Shi Cao can treat, cure, or prevent allergic rhinitis, cancer, alopecia, or any other medical condition. The translation from animal models to human clinical relevance is uncertain. This page does not endorse E Bu Shi Cao as a treatment for any condition.

Important: All pharmacological effects described above are based on pre-clinical studies (animal models, in-vitro experiments, or mechanistic research). They do not constitute evidence of clinical efficacy in humans. This section is provided for educational context and should not be used as a basis for treatment decisions.

General safety profile: E Bu Shi Cao is widely used in TCM practice and is generally considered to have a favorable safety profile when used appropriately in formula combinations. However, like all herbal products, it is not free of risk. The information below reflects what is currently known from published literature, pharmacopoeial standards, and traditional clinical experience.

Yin deficiency and Heat patterns: In traditional TCM theory, E Bu Shi Cao is pungent and warm in nature. Individuals with Yin deficiency patterns — characterized by dry mouth and throat, night sweats, a red tongue with little coating, and a thin, rapid pulse — should generally avoid or use E Bu Shi Cao with caution. Its warm, dispersing nature may theoretically further damage Yin fluids and exacerbate Heat signs. Similarly, those with excessive Heat patterns or febrile diseases with significant fluid depletion should use this herb only under professional guidance.

Allergic reactions: E Bu Shi Cao belongs to the Asteraceae (Compositae) family, which includes many plants known to cause allergic reactions in sensitive individuals, such as ragweed, chrysanthemums, marigolds, and daisies. Individuals with known allergies to Asteraceae plants should avoid E Bu Shi Cao. Allergic reactions, while rare, may present as skin rash, itching, nasal irritation, or respiratory symptoms, particularly when the herb is used in nasal insufflation form.

Pregnancy and lactation: E Bu Shi Cao does not have a specific traditional contraindication during pregnancy when used in formula combinations under professional guidance. However, because of its pungent, warm, and dispersing nature, it is traditionally considered that pregnant women should use it with caution. Modern pre-clinical data on E Bu Shi Cao constituents in pregnancy are insufficient to fully establish safety. Do not use E Bu Shi Cao during pregnancy without direct supervision from a qualified healthcare professional.

Drug interactions: Pre-clinical data suggest that certain constituents in E Bu Shi Cao, including brevilin A, may affect JAK-STAT signaling pathways, which could theoretically interact with immunosuppressive or immunomodulatory medications. Sesquiterpene lactones from E Bu Shi Cao have also been shown to modulate cytochrome P450 enzyme activity in pre-clinical models, which could theoretically alter the metabolism of drugs processed through these pathways. Clinical interaction data for whole-herb E Bu Shi Cao are very limited. Consult a qualified healthcare professional before combining E Bu Shi Cao with any prescription medications.

Reported side effects: Based on available reports, side effects associated with E Bu Shi Cao are generally rare and mild when used at appropriate doses. Occasional reports include mild gastrointestinal discomfort (nausea, abdominal bloating), nasal irritation (particularly with insufflation use), dizziness, or allergic reactions (skin rash) in sensitive individuals. Any suspected adverse effects should be reported to a healthcare professional.

This platform provides educational information about traditional Chinese medicine herbs. It does not recommend, endorse, or prescribe the use of E Bu Shi Cao or any other herbal product for the treatment of any medical condition. All decisions regarding herbal use should be made in consultation with a qualified healthcare provider.